全球首个癌症疫苗背后：Moderna扛下多年质疑，正在成为一家AI公司！

TL;DR - Moderna says its personalized mRNA cancer vaccine intismeran (mRNA-4157) succeeded in Phase III, supporting its expansion beyond infectious-disease vaccines. The company is positioning AI as the core engine for patient-specific target selection, mRNA design, and automated manufacturing.

• AI predicts which mutations in an individual patient’s tumor are most immunogenic, selects vaccine targets, and helps design candidate mRNA sequences within hours.
• Personalized vaccines require a separate formulation per patient, making algorithmic coordination of synthesis, quality control, and delivery essential at scale.
• Moderna’s Lucy R&D system reportedly closes the loop between sequence generation, automated DNA-to-mRNA production, high-throughput testing, and model updates.
• The reported clinical milestone strengthens the case that mRNA can serve as a programmable therapeutic platform for cancer, immune disorders, and rare diseases—not only vaccines against viruses.